Immuno-oncology

Dasgupta, A; Spencer, H

Incysus has licensed technology from Emory and its collaborators that uses genetically modified gamma-delta T cells to treat solid tumor cancers. In fall 2017, the company filed its Investigational New Drug (IND) application to test the safety and efficacy in patients with glioblastoma.